4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Wednesday,Weiss Ratings reports.

FDMT has been the subject of a number of other research reports. Bank of America lowered their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Chardan Capital lowered their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group lowered their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.56.

4D Molecular Therapeutics Stock Down 2.5%

Shares of NASDAQ:FDMT opened at $4.36 on Wednesday. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93. The stock has a market cap of $201.98 million, a P/E ratio of -1.53 and a beta of 2.84. The business’s 50 day moving average is $3.37 and its 200 day moving average is $4.58.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $41,000. AQR Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $46,000. KLP Kapitalforvaltning AS purchased a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $48,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.